Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors

被引:17
作者
Miles, Dillon H. [1 ]
Yan, Xuelei [1 ]
Thomas-Tran, Rhiannon [1 ]
Fournier, Jeremy [1 ]
Sharif, Ehesan U. [1 ]
Drew, Samuel L. [1 ]
Mata, Guillaume [1 ]
Lawson, Kenneth, V [1 ]
Ginn, Elaine [1 ]
Wong, Kent [1 ]
Soni, Divyank [1 ]
Dhanota, Puja [1 ]
Shaqfeh, Stefan G. [1 ]
Meleza, Cesar [1 ]
Chen, Ada [1 ]
Pham, Amber T. [1 ]
Park, Timothy [1 ]
Swinarski, Debbie [1 ]
Banuelos, Jesus [1 ]
Schindler, Ulrike [1 ]
Walters, Matthew J. [1 ]
Walker, Nigel P. [1 ]
Zhao, Xiaoning [1 ]
Young, Stephen W. [1 ]
Chen, Jie [1 ]
Jin, Lixia [1 ]
Leleti, Manmohan Reddy [1 ]
Powers, Jay P. [1 ]
Jeffrey, Jenna L. [1 ]
机构
[1] Arcus Biosci Inc, Hayward, CA 94545 USA
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 11期
关键词
PI3K gamma; inhibitor; selective; azaindole; immunomodulation; cancer;
D O I
10.1021/acsmedchemlett.0c00387
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The successful application of immunotherapy in the treatment of cancer relies on effective engagement of immune cells in the tumor microenvironment. Phosphoinositide 3-kinase gamma (PI3K gamma) is highly expressed in tumor-associated macrophages, and its expression levels are associated with tumor immunosuppression and growth. Selective inhibition of PI3K gamma offers a promising strategy in immunooncology, which has led to the development of numerous potent PI3K gamma inhibitors with variable selectivity profiles. To facilitate further investigation of the therapeutic potential of PI3K gamma inhibition, we required a potent and PI3K gamma-selective tool compound with sufficient metabolic stability for use in future in vivo studies. Herein, we describe some of our efforts to realize this goal through the systematic study of SARs within a series of 7-azaindole-based PI3K gamma inhibitors. The large volume of data generated from this study helped guide our subsequent lead optimization efforts and will inform further development of PI3K gamma-selective inhibitors for use in immunomodulation.
引用
收藏
页码:2244 / 2252
页数:9
相关论文
共 31 条
[21]   Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases [J].
Perry, Matthew W. D. ;
Abdulai, Raolat ;
Mogemark, Mickael ;
Petersen, Jens ;
Thomas, Matthew J. ;
Valastro, Barbara ;
Eriksson, Annika Westin .
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (10) :4783-4814
[22]   Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration [J].
Sasaki, T ;
Irie-Sasaki, J ;
Jones, RG ;
Oliveira-dos-Santos, AJ ;
Stanford, WL ;
Bolon, B ;
Wakeham, A ;
Itie, A ;
Bouchard, D ;
Kozieradzki, I ;
Joza, N ;
Mak, TW ;
Ohashi, PS ;
Suzuki, A ;
Penninger, JM .
SCIENCE, 2000, 287 (5455) :1040-1046
[23]  
Shvartsbart A., 2019, WIPO, Patent No. [2019/126505 A1, 2019126505]
[24]   PI3K inhibitors in inflammation, autoimmunity and cancer [J].
Stark, Anne-Katrien ;
Sriskantharajah, Srividya ;
Hessel, Edith M. ;
Okkenhaug, Klaus .
CURRENT OPINION IN PHARMACOLOGY, 2015, 23 :82-91
[25]   PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting [J].
Thorpe, Lauren M. ;
Yuzugullu, Haluk ;
Zhao, Jean J. .
NATURE REVIEWS CANCER, 2015, 15 (01) :7-24
[26]   Signalling through the lipid products of phosphoinositide-3-OH kinase [J].
Toker, A ;
Cantley, LC .
NATURE, 1997, 387 (6634) :673-676
[27]   Evaluating the Utility of a Bioluminescent ADP-Detecting Assay for Lipid Kinases [J].
Vidugiriene, Jolanta ;
Zegzouti, Hicham ;
Goueli, Said A. .
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2009, 7 (06) :585-597
[28]   Structure and function of phosphoinositide 3-kinases [J].
Wymann, MP ;
Pirola, L .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 1998, 1436 (1-2) :127-150
[29]   Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity [J].
Yang, Chengbin ;
Zhang, Xi ;
Wang, Yi ;
Yang, Yongtai ;
Liu, Xiaofeng ;
Deng, Mingli ;
Jia, Yu ;
Ling, Yun ;
Meng, Ling-hua ;
Zhou, Yaming .
ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (08) :875-880
[30]   Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development [J].
Zhao, Hua-fu ;
Wang, Jing ;
Shao, Wei ;
Wu, Chang-peng ;
Chen, Zhong-ping ;
To, Shing-shun Tony ;
Li, Wei-ping .
MOLECULAR CANCER, 2017, 16